Search

Author/Creator Chi, Andy

1. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9980 (9th May 2015)

Authors:
Moskowitz, Craig H; Nademanee, Auayporn; Masszi, Tamas; Agura, Edward; Holowiecki, Jerzy; Abidi, Muneer H; Chen, Andy I; Stiff, Patrick; Gianni, Alessandro M; Carella, Angelo; Osmanov, Dzhelil; Bachanova, Veronika; Sweetenham, John; Sureda, Anna; Huebner, Dirk; Sievers, Eric L; Chi, Andy; Larsen,...
Journal:
Lancet
Issue:
Volume 385:Issue 9980(2015)
Page Start:
1853
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis. (July 2015)

Authors:
Bonthapally, Vijayveer; Yang, Hongbo; Ayyagari, Rajeev; Tan, Ruo-Ding; Cai, Sean; Wu, Eric; Gautam, Ashish; Chi, Andy; Huebner, Dirk
Journal:
Current medical research and opinion
Issue:
Volume 31:Number 7(2015:Jul.)
Page Start:
1377
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗